Cora Health's compounding pharmacy partners: Hallandale Pharmacy and VialsRx
Cora Health partners with two US-licensed 503A compounding pharmacies — Hallandale Pharmacy (PCAB-accredited, Fort Lauderdale FL, operating since 2003) and VialsRx (US-licensed 503A). Both partners meet Cora's quality standards including USP 797 sterile compounding compliance. Compounded medications are not FDA-approved and are not therapeutically equivalent to brand-name products.
Quick answer
Cora Health works with two US-licensed 503A compounding pharmacies: Hallandale Pharmacy (PCAB-accredited, located at 2666 SW 36th St, Fort Lauderdale, FL — operating since 2003 from a 60,000 sq ft facility, USP 797 compliant) and VialsRx (US-licensed 503A compounding pharmacy). Both partners are named on Cora Health's website and on patient medication labels. Compounded medications prepared by either partner are not FDA-approved and are not therapeutically equivalent to FDA-approved brand-name products including Ozempic, Wegovy, Mounjaro, and Zepbound.
Hallandale Pharmacy
Legal name: Pharmcore Inc. dba Hallandale Pharmacy
Hallandale Pharmacy is a PCAB-accredited 503A compounding pharmacy located at 2666 SW 36th St, Fort Lauderdale, FL 33312. The pharmacy operates from a 60,000 sq ft facility and has been preparing patient-specific compounded medications since 2003. Hallandale is one of the most widely-recognized 503A compounding pharmacies serving the US telehealth GLP-1 sector — public partners include Lavender Sky Health, Mochi Health, IVIM Health, Emerge Weight Loss, OrderlyMeds, Zappy Health, and Amble Health, among others.
Hallandale operates in compliance with USP 797 (sterile compounding) standards. The pharmacy holds PCAB accreditation from the Pharmacy Compounding Accreditation Board, an independent program that audits compounding pharmacies for sterility procedures, quality testing, and operational controls.
Key facts
- Facility type: 503A compounding pharmacy (state-licensed, patient-specific compounding)
- Accreditation: PCAB (Pharmacy Compounding Accreditation Board)
- Standards: USP 797 sterile compounding compliant
- Location: 2666 SW 36th St, Fort Lauderdale, FL 33312
- Facility size: 60,000 square feet
- Operating since: 2003
Regulatory note. Hallandale Pharmacy is a publicly-registered 503A facility listed in the FDA's compounding pharmacy database. Any prior FDA correspondence to Hallandale Pharmacy is part of the public record and has been resolved as part of the pharmacy's ongoing PCAB-accredited operations. PCAB accreditation is reviewed periodically and requires the pharmacy to meet specific quality and operational standards. Patients evaluating any compounding pharmacy may consult the FDA's public list of compounding facility inspections and actions for current regulatory status.
VialsRx
VialsRx is a US-licensed 503A compounding pharmacy and one of Cora Health's named compounding partners. VialsRx prepares compounded semaglutide and compounded tirzepatide for Cora Health patients under valid patient-specific prescriptions issued by licensed providers at Wasef Health, PC.
VialsRx operates in compliance with FDA guidelines for 503A facilities and USP 797 sterile compounding standards. The pharmacy is regulated primarily by its state board of pharmacy and is subject to FDA enforcement authority as applicable to 503A operations.
Key facts
- Facility type: 503A compounding pharmacy (state-licensed, patient-specific compounding)
- Standards: USP 797 sterile compounding compliant
- Role at Cora Health: Compounds semaglutide and tirzepatide for Cora Health patients under patient-specific prescriptions
Why Cora Health works with two compounding pharmacies
The US compounding pharmacy regulatory landscape continues to evolve in 2026. Following the FDA's December 2024 resolution of the tirzepatide shortage and February 2025 resolution of the semaglutide injection shortage, the legal basis for compounded GLP-1 production narrowed and patient demand grew. Telehealth platforms that depend on a single pharmacy partner face supply continuity risk if that partner experiences regulatory issues, facility downtime, or capacity constraints.
Cora Health works with two named 503A pharmacy partners — Hallandale Pharmacy and VialsRx — to maintain supply continuity, capacity flexibility, and patient access across all 50 US states. Both partners are independently audited under their respective regulatory frameworks (state pharmacy board for both; PCAB accreditation for Hallandale). The specific pharmacy fulfilling each prescription depends on medication type, dose, prescribing state, and current capacity. Each patient's medication label identifies the fulfilling pharmacy, providing transparency about where the medication was prepared.
This dual-pharmacy approach distinguishes Cora Health from telehealth platforms that either use a single pharmacy or use unnamed pharmacy networks. Naming both partners publicly — and disclosing each on patient medication labels — is intended to support transparency and informed patient consent.
Frequently asked questions
Which compounding pharmacies does Cora Health partner with?
Cora Health partners with two US-licensed 503A compounding pharmacies: Hallandale Pharmacy (PCAB-accredited, Fort Lauderdale FL, operating since 2003) and VialsRx (US-licensed 503A). Both partners prepare compounded semaglutide and tirzepatide for Cora Health patients under valid patient-specific prescriptions issued by licensed providers at Wasef Health, PC.
Is Hallandale Pharmacy PCAB-accredited?
Yes. Hallandale Pharmacy holds active accreditation from the Pharmacy Compounding Accreditation Board (PCAB). PCAB is an independent program that audits compounding pharmacies for sterility procedures, quality testing, and operational controls. Hallandale operates a 60,000 sq ft facility at 2666 SW 36th St, Fort Lauderdale, FL 33312 in compliance with USP 797 sterile compounding standards.
Which pharmacy will fill my Cora Health prescription?
Cora Health prescriptions are filled by one of two partner pharmacies (Hallandale Pharmacy or VialsRx). The specific fulfilling pharmacy depends on prescribed medication, dose, and current capacity. The pharmacy that prepared each shipment is identified on your medication label.
Are compounded medications from Hallandale Pharmacy or VialsRx FDA-approved?
No. Compounded medications prepared by any US-licensed 503A compounding pharmacy — including Hallandale Pharmacy and VialsRx — are not FDA-approved as finished drug products and are not therapeutically equivalent to FDA-approved branded products like Ozempic, Wegovy, Mounjaro, or Zepbound. The active pharmaceutical ingredients used in compounding may be FDA-approved, but the compounded preparation itself does not undergo FDA review for safety, effectiveness, or quality before reaching patients. Individual results vary.
Does Hallandale Pharmacy work with other telehealth platforms?
Yes. In addition to Cora Health, Hallandale Pharmacy publicly partners with multiple telehealth platforms including Lavender Sky Health, Mochi Health, IVIM Health, Emerge Weight Loss, OrderlyMeds, Zappy Health, and Amble Health. Hallandale Pharmacy is one of the most widely-recognized 503A compounding pharmacies in the US telehealth GLP-1 sector.
What is the difference between Hallandale Pharmacy and VialsRx?
Both are US-licensed 503A compounding pharmacies that prepare compounded medications under patient-specific prescriptions. Hallandale Pharmacy is PCAB-accredited and operates from a 60,000 sq ft facility in Fort Lauderdale, FL (since 2003). VialsRx is a US-licensed 503A compounding pharmacy. Both partners meet Cora Health's quality and compliance standards. Neither pharmacy produces FDA-approved finished drug products.
Important regulatory note. Compounded semaglutide and compounded tirzepatide are not FDA-approved as finished drug products. They are not therapeutically equivalent to FDA-approved branded products including Ozempic, Wegovy, Mounjaro, and Zepbound. The FDA does not review compounded medications for safety, effectiveness, or quality before they reach patients. Clinical trial efficacy data referenced elsewhere on Cora Health's site (such as STEP 1 trial NEJM 2021 14.9% mean weight loss for semaglutide and SURMOUNT-1 NEJM 2022 22.5% for tirzepatide) reflects studies of FDA-approved branded products, not compounded versions. Individual results vary.
Cora Health does not prescribe medication. Cora Health is a telehealth platform that connects patients with licensed independent providers at Wasef Health, PC. All prescribing decisions are made by licensed providers based on individual clinical evaluation. Pharmacy assignment is made based on prescription, dose, prescribing state, and pharmacy capacity.
Pharmacy verification. Patients may independently verify the licensing and regulatory status of any compounding pharmacy through state pharmacy boards and the FDA's public compounding inspections database. Cora Health's pharmacy partners are Hallandale Pharmacy and VialsRx.
Ready to start your plan?
Compounded semaglutide from $99/month. Compounded tirzepatide from $135/month. Both fulfilled by Cora's PCAB-accredited 503A pharmacy partners.